The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Subscribe To Our Newsletter & Stay Updated
